Quanterix Corp (OQ:QTRX)

Business Focus: Advanced Medical Equipment & Technology

Mar 21, 2024 05:30 pm ET
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in the United States and abroad. Multiple patents—including U.S. Patent No. 11,275,092—are directed specifically to our novel approach t
Mar 04, 2024 09:00 am ET
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.
Feb 29, 2024 04:00 pm ET
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.
Feb 26, 2024 06:58 pm ET
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31,
Feb 26, 2024 09:00 am ET
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer’s disease (AD) diagnosis. These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
Feb 23, 2024 04:30 pm ET
Quanterix to Present at Cowen’s 44th Annual Health Care Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made availabl
Feb 16, 2024 04:00 pm ET
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Mas
Dec 12, 2023 04:00 pm ET
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 42nd Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Wednesday, January 10, 2024, at 5:
Nov 13, 2023 04:00 pm ET
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will speak in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 202
Nov 13, 2023 07:00 am ET
Sotera Health Appoints Karen Flynn to Board of Directors
Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new...
Nov 06, 2023 05:56 pm ET
Quanterix Releases Operating Results for Third Quarter 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023.
Nov 06, 2023 04:50 pm ET
Quanterix Releases Operating Results for Third Quarter 202
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023.
Oct 30, 2023 04:00 pm ET
Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the third quarter 2023 after the market closes on Monday, November 6, 2023, and will host a webcast and conference call on Tuesday, November 7, 2023 at 8:30 a.m. E.T.
Oct 24, 2023 04:30 pm ET
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217. This lab developed test marks a major advance in the performance of scalable immunoassay-based blood biomarker tests intended for assessing amyloid pathology in individuals with memory complaints.
Oct 23, 2023 08:30 pm ET
Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a license agreement with Janssen Sciences Ireland UC (Janssen), a Johnson & Johnson (J&J) Company. Under this agreement, Quanterix will receive worldwide, non-exclusive rights to J&J’s extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix’s position at the forefront of the Alzheimer's Disease (AD) biomarker field.
Sep 28, 2023 05:00 pm ET
Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer’s Disease Day on Tuesday, October 3, 2023. The panel, Infrastructure considerations: Outlook for blood-bas
Sep 05, 2023 08:00 am ET
Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will take part in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023 at 3:35 p.m. ET. The pres
Aug 21, 2023 04:30 pm ET
William P. Donnelly Appointed to Quanterix’s Board of Directors
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors.
Aug 09, 2023 08:30 am ET
Quanterix Appoints Vandana Sriram as Chief Financial Officer
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Michael Doyle, who has served as the Company’s CFO since July 2021. As previously announced, Mike will transition to the role of Executive Director, Finance, focusing on strategic growth programs until his retirement in March 2024.
Aug 07, 2023 05:13 pm ET
Quanterix Releases Operating Results for Second Quarter 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023.
Aug 03, 2023 08:00 am ET
Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the
Jul 31, 2023 08:00 am ET
Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that its Simoa® technology supported a large international study to establish sNfL reference ranges to assess neurological disease activity in children and adolescents, according to a recent study published in The Lancet Neurology. Researchers from the University Hospital Basel and University of Basel, led by Professor Jens Kuhle, leveraged Simoa’s ability to precisely detect the sNfL protein at ultra-low levels, enabling a large-
Jul 20, 2023 08:00 am ET
Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T.
Jul 06, 2023 05:37 pm ET
Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD). The LucentAD test, which will be available to healthcare providers as an aid in conjunction with other diagnostic tools, provides clinicians with a simplified process to quickly assess the likelihood of a patient having amyloid pathology consistent with AD. This infor
Jun 07, 2023 04:00 pm ET
Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs Annual Global Healthcare Conference on June 14, 2023 at 10:40 a.m., PT. The presentation will be available virtually and listeners ca
May 09, 2023 04:00 pm ET
Quanterix Releases Operating Results for First Quarter 2023
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023.
May 02, 2023 04:30 pm ET
Quanterix’s First Quarter 2023 Earnings Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, May 9, 2023, to discuss its first quarter 2023 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s Presi
Apr 25, 2023 04:30 pm ET
FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that blood-based NfL measurements provided compelling support for the FDA’s accelerated approval of tofersen for treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a devastating rare genetic form of ALS. This is the first known case in which a blood biomarker was successfully used as a surrogate endpoint for a neurology therapeutic trial to gain accelerated approval, highlighting the potential for other
Mar 08, 2023 04:30 pm ET
Quanterix to Participate in Barclays Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:35 p.m., EDT. In addition, the company will also host in-person one-on-one me
Mar 06, 2023 08:09 am ET
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2022.
Feb 28, 2023 04:30 pm ET
Quanterix to Present at Cowen’s 43rd Annual Health Care Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 43rd Annual Health Care Conference. Quanterix’s session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST and will be made availabl
Feb 27, 2023 02:03 pm ET
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud To
Feb 24, 2023 04:30 pm ET
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud To
Jan 09, 2023 04:30 pm ET
Quanterix Announces Appointment of Brian Blaser to Board of Directors
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023.
Jan 09, 2023 08:30 am ET
Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the validation of a Laboratory Developed Test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.
Jan 03, 2023 04:00 pm ET
Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Thursday, Jan. 12, 2023, at 12 p.m., PST a
Dec 05, 2022 04:36 pm ET
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the
Nov 16, 2022 04:30 pm ET
Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced plans to participate in the upcoming
Nov 10, 2022 04:30 pm ET
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the
Nov 08, 2022 04:00 pm ET
Quanterix Corporation Releases Operating Results for Third Quarter 2022
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced operating results for the three months ended September 30, 2022.
Nov 01, 2022 04:30 pm ET
Quanterix’ Third Quarter 2022 Earnings Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, November 8, 2022, to discuss its third quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s
Aug 08, 2022 04:02 pm ET
Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors
Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors.
Aug 08, 2022 04:01 pm ET
Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance
Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced operating results for the three months ended June 30, 2022.
Aug 03, 2022 04:30 pm ET
Quanterix to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the
Aug 01, 2022 04:30 pm ET
Quanterix’ Second Quarter 2022 Earnings Conference Call
Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’
Jul 27, 2022 04:45 pm ET
Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.
Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced the validation of a laboratory developed test (LDT) to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer’s disease (AD). Quanterix’ LDT – the first pTa
Jun 09, 2022 04:30 pm ET
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the
Jun 06, 2022 08:36 am ET
Quanterix Announces Appointment of Karen A. Flynn to Board of Directors
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.
May 10, 2022 08:00 am ET
Quanterix Corporation Releases Operating Results for First Quarter 2022
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the three months ended March 31, 2022.
May 03, 2022 08:30 am ET
Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2022 before the start of trading on May 10, 2022. Company management will host a conference call at 8:30 a.m. EST to discuss Quante
Apr 22, 2022 08:30 am ET
Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Simoa® neurofilament light chain (NfL) plasma test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as a prognostic aid in assessing the
Apr 04, 2022 04:30 pm ET
Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its
Mar 29, 2022 04:30 pm ET
Quanterix Receives Funding from the Alzheimer’s Drug Discovery Foundation to Accelerate Alzheimer’s Disease Diagnostic Plasma Test Development
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has partnered with the
Mar 09, 2022 04:30 pm ET
Quanterix to Participate in Barclays Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present in-person at the Barclays Global Healthcare Conference on March 15, 2022 at 10:45 a.m., EST. For those interested in
Mar 03, 2022 04:30 pm ET
Quanterix to Participate in The Cowen 42nd Annual Health Care Conference On March 9
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present virtually at
Mar 01, 2022 07:30 am ET
Quanterix Announces Executive Leadership Succession Plan
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its executive leadership succession plan designed to leverage the Company’s strong foundation for growth. Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board and President Masoud Toloue will succeed Hrusovsky as CEO and join Quanterix’ Board of Directors. Hrusovsky will focus on key strategic initiatives, Board evolution and important customer, partner and investor relatio
Mar 01, 2022 07:30 am ET
Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease. As part of the collaboration, Quanterix will receive a non-exc
Mar 01, 2022 07:30 am ET
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.
Feb 28, 2022 02:29 pm ET
Quanterix Corporation Garners Five Best Places to Work Awards from Comparably
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized by leading workplace culture and corporate brand reputation platform,
Feb 23, 2022 04:30 pm ET
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for fourth quarter 2021 before the start of trading on Tuesday, March 1, 2022. Company management will host a conference call at 8:30 a.m. EST to dis
Feb 09, 2022 09:00 am ET
Quanterix to Participate in the SVB Leerink Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky, will present virtually at the
Feb 07, 2022 06:43 pm ET
UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology is powering groundbreaking neurodegenerative disease research at the recently launched UK Dementia Research Institute (DRI) Biomarker Factory, where Professor Henrik Zett
Jan 26, 2022 11:30 am ET
Quanterix’ Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology was instrumental in revealing high prevalence of Epstein-Barr virus (EBV) associated with multiple sclerosis (MS), according to a recent
Jan 13, 2022 07:30 am ET
Quanterix Provides Operational and Preliminary Financial Highlights
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.
Jan 06, 2022 04:30 pm ET
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, and Founder of
Nov 17, 2021 04:15 pm ET
Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized on the
Nov 16, 2021 09:20 am ET
Quanterix’ Simoa® Technology Powers Advances in Alzheimer’s Disease Research Presented at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its ultra-sensitive Simoa® technology enabled important advances in ongoing clinical trials for the treatment of Alzheimer’s disease. The findings were presented at the
Nov 11, 2021 04:30 pm ET
Quanterix to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that members of its executive leadership team will participate in a virtual fireside chat discussion at the
Nov 08, 2021 01:21 pm ET
Quanterix Co-Inventor of Simoa® David Walt Receives Kabiller Prize in Nanoscience and Nanomedicine
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, has announced that David Walt, co-inventor of Simoa®, was awarded the
Nov 04, 2021 04:01 pm ET
Quanterix Corporation Releases Operating Results for Third Quarter of 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the three months ending September 30, 2021.
Oct 28, 2021 04:30 pm ET
Quanterix Corporation to Release Third Quarter 2021 Financial Results on Nov. 4, 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for third quarter 2021 after the close of trading on Nov. 4, 2021. Company management will host a conference call at 4:30 p.m. EDT to discuss Quanterix’ finan
Oct 11, 2021 04:05 pm ET
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based pTau-181 Assay for Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheim
Sep 20, 2021 08:26 am ET
Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, presented a webinar on Sept. 16, 2021, hosted by Kevin Hrusovsky, Quanterix Chairman and Chief Executive Officer, with leading pathologist Dr. John Roback, M.D., Ph.D., Professor of Pathology and Laboratory
Sep 13, 2021 05:42 pm ET
Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that the Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) label for its Simoa® SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab an
Sep 10, 2021 05:28 pm ET
Quanterix to Host Webinar with Leading Pathologist from Emory Medical Laboratories: “COVID-19 Testing in a Residential University Setting: Implementation, Insights, and Learnings”
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a webinar hosted by Kevin Hrusovsky, Quanterix Chairman and Chief Executive Officer, with leading pathologist Dr. John Roback, M.D., Ph.D., Professor of Pathology and Laboratory Medicine, Executi
Aug 27, 2021 08:19 am ET
Quanterix Releases Statement
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today released the following statement in response to news reports related to Cassava Sciences.
Aug 09, 2021 04:30 pm ET
Quanterix to Participate in the Canaccord Genuity 41st Annual Growth Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. ET. Hr
Aug 06, 2021 07:57 am ET
Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Eli Lilly and Company, a global healthcare company, presented new data from Lilly’s Phase 2 TRAILBLAZER-ALZ study at AAIC 2021 utilizing Quanterix’ highly sensitive Simoa® technology. Th
Aug 05, 2021 04:18 pm ET
Quanterix Corporation Releases Operating Results for Second Quarter of 2021
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2021.
Jul 28, 2021 07:04 am ET
Quanterix Corporation to Release Second Quarter 2021 Financial Results on Aug. 5, 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2021 after the close of trading on Aug. 5, 2021. Company management will host a conference call at 4:30pm ET to discuss Quanterix’ financial resul
Jun 28, 2021 04:08 pm ET
Quanterix Appoints Michael Doyle as Chief Financial Officer
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Michael Doyle to the position of Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who has served as the Company’s Interim Chie
Jun 07, 2021 10:13 am ET
Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Investigation of Plasma Neurofilament Light’s Role in Dementia Diagnosis
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its
Jun 02, 2021 11:02 am ET
Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference and Appear on the June 3 Episode of The Bio Report
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm E
May 11, 2021 08:00 am ET
Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics
Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021.
May 05, 2021 04:01 pm ET
Quanterix Corporation Releases Operating Results for First Quarter 2021
Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021.
Apr 28, 2021 04:30 pm ET
Quanterix Corporation to Release First Quarter 2021 Financial Results on May 5, 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for first quarter 2021 after the close of trading on Wednesday, May 5, 2021. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ fi
Apr 28, 2021 07:30 am ET
Quanterix Appoints Laurie Olson to Board of Directors
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the appointment of Laurie Olson to its Board of Directors, effective April 27, 2021.
Apr 22, 2021 03:29 pm ET
Quanterix Webinar: Recent Advancements in Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test for Alzheimer’s Disease
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a webinar with leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. With several pharmace
Apr 21, 2021 07:10 am ET
Quanterix Announces Appointment of Interim Chief Financial Officer
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has appointed Shawn Stetson as the Company's interim chief financial officer, effective May 11, 2021. Mr. Stetson will assume his new responsibilities upon the departure of the Compan
Mar 26, 2021 06:47 am ET
Quanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples
“Despite the rapid proliferation of COVID-19 testing, the global community continues to struggle to overcome critical challenges with the accuracy, cost and availability of diagnostic tests, and with access to research tools that could help to enable a highly tailored approach to COVID-19 patient care,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix and Founder, Powering Precision Health (PPH). “While vaccine deployment continues at an aggressive pace, COVID-19 testing and clinical research tools will remain a global priority in the months to come. Highly sens
Mar 17, 2021 04:01 pm ET
Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021)
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various blood-based neurology biomarker assays were used by leading research teams to power 30 total oral and poster presentations at this year’s
Mar 02, 2021 04:03 pm ET
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2020.
Feb 25, 2021 06:05 pm ET
Quanterix’ Kevin Hrusovsky to Present at the Cowen 41st Annual Health Care Conference on March 3 and Appear on the Feb. 26 Episode of the Health Care Rounds Podcast
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be delivering a virtual presentation at the
Feb 23, 2021 11:19 am ET
Quanterix Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call at 4:30 p.m., ET to discus
Feb 18, 2021 11:59 am ET
Quanterix to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be presenting at the 10th Annual SVB Leerink Global Healthcare Conference, being held virtually from
Feb 12, 2021 02:08 pm ET
Quanterix Announces Simoa® Joint Laboratory with WuXi AppTec
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into an agreement to open a joint Simoa laboratory with
Feb 08, 2021 03:12 pm ET
Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $287.5 million.
Feb 04, 2021 07:00 am ET
Quanterix Prices Public Offering of Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $250 million. Quanterix has also granted the underwriters a 30-day option to purchase up
Feb 03, 2021 04:25 pm ET
Quanterix Announces Proposed Public Offering of $200.0 Million of its Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price less the underwriting discounts and commissions. All of the shares in the offering will be sold by Quanterix. The offering is subject to market and other conditions, and there can b
Jan 22, 2021 03:39 pm ET
Quanterix to Participate in PMWC 2021 COVID-19 Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder,
Jan 13, 2021 08:30 am ET
Quanterix Provides Operational and Preliminary Financial Highlights
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ended December 31, 2020.
Jan 11, 2021 04:30 pm ET
Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® SARS-CoV-2 N Protein Antigen Test that can be run on the
Jan 06, 2021 04:06 pm ET
Quanterix Corporation to Present At 39th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President, and Founder of
Dec 28, 2020 06:46 pm ET
Quanterix Receives FDA Emergency Use Authorization for Semi-Quantitative Antibody Test
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® Semi-Quantitative SARS-CoV-2 IgG Antibody Test that can be run on the
Dec 09, 2020 09:00 am ET
Quanterix to Participate in Contagion Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder,
Nov 18, 2020 04:28 pm ET
 Quanterix Appoints William Geist as Chief Operating Officer
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has named William Geist to the position of chief operating officer (COO), effective November 16, 2020.
Nov 13, 2020 12:36 pm ET
Quanterix to Participate in the Canaccord Medical Technologies and Diagnostics Forum
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m.
Nov 05, 2020 04:16 pm ET
Quanterix Corporation Releases Operating Results for Third Quarter 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending September 30, 2020.
Oct 30, 2020 05:32 pm ET
908 Devices Names Kevin Hrusovsky, 30-year Biotechnology Veteran and Founder of Powering Precision Health, as Chairman of its Board of Directors
BOSTON, Oct. 30, 2020 /PRNewswire/ -- 908 Devices, a pioneer of purpose-built handheld and desktop Mass Spec devices for chemical and biomolecular analysis, today announced the appointment of Kevin Hrusovsky as the Chairman of its Board of Directors. Mr. Hrusovsky, who has served on the 908 Devices Board of Directors since 2013, is a biotech entrepreneur and healthcare visionary with a passion for revolutionizing healthcare and a proven track record of commercializing disruptive technologies.  
Oct 29, 2020 02:40 pm ET
Quanterix Corporation to Release Third Quarter 2020 Financial Results on November 5, 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for third quarter 2020 after the close of trading on Thursday, November 5, 2020. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix
Oct 28, 2020 11:37 am ET
Kevin Hrusovsky to Speak at Precision Medicine Leaders Summit’s Precision Oncology Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President and Founder, Powering Precision Health (PPH), Kevin Hrusovsky, will speak today at the
Oct 06, 2020 03:32 pm ET
Quanterix Receives National Institutes of Health RADx Contract to Advance Antigen Test for SARS-CoV-2 (COVID-19)
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has entered into a Phase 2 contract with the National Institutes of Health (NIH) through its Rapid Acceleration of Diagnostics (RADx℠) initiative. The contract, which has a total award value of $18.2
Oct 05, 2020 04:01 pm ET
Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications.
Sep 10, 2020 09:00 am ET
Quanterix’ Simoa Technology Supports 42 Scientific Presentations at MSVirtual2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa® technology has been used by leading research teams to power 42 studies presented at the 8th Joint ACTRIMS-ECTRIMS Meeting,
Aug 11, 2020 04:34 pm ET
Quanterix Announces Closing of Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 3,048,774 shares of its common stock at a public offering price of $32.00 per share, including 397,666 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $97.6 million.
Aug 11, 2020 09:00 am ET
Quanterix to Participate in the Canaccord Genuity 40th Annual Growth Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky, will participate in a virtual fireside chat discussion at the Canaccord Genuity 40th Annual Growth Conference on August 13 at 10:00 a.m., EDT.
Aug 06, 2020 10:12 pm ET
Quanterix Prices Public Offering of Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,651,108 shares of its common stock at a public offering price of $32.00 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $84.8 million. Quanterix has also granted the underwriters a 30-day option to purchase u
Aug 06, 2020 04:11 pm ET
Quanterix Announces Proposed Public Offering of Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price less the underwriting discounts and commissions. All of the shares in the offering will be sold by Quanterix. The offering is subject to market and other conditions, and there can be no assurance as
Aug 04, 2020 04:29 pm ET
Quanterix Corporation Releases Operating Results for Second Quarter 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2020.
Aug 03, 2020 09:08 am ET
Quanterix Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2020 after the close of trading on Tuesday, August 4, 2020. Company management will host a conference call at 5:00 p.m., ET t
Aug 03, 2020 08:36 am ET
Quanterix Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2020 after the close of trading on Tuesday, August 4, 2020. Company management will host a conference call at 5:00 p.m., ET t
Jul 29, 2020 09:30 am ET
Quanterix sNfL Assay and Simoa Technology First to Measure Neuronal Injury in COVID-19 Patients’ Blood
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that quantitative testing using its sNfL Assay and
Jul 27, 2020 07:00 am ET
Quanterix to Participate in Alzheimer’s Association International Conference (AAIC) 2020
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced its participation as a speaker and exhibitor at the
Jul 20, 2020 10:41 am ET
Quanterix’ Simoa Technology Powers New Insights into COVID-19 Immune Response and Reveals Indicators of Disease Severity
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that researchers across the globe are deploying its
Jun 26, 2020 09:37 am ET
 Quanterix Corporation CEO to Present at MassBio: Possible Talk Series
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Chairman and Chief Executive Officer of Quanterix and Founder of the non-profit
Jun 11, 2020 04:10 pm ET
Quanterix to Host Virtual Annual Meeting of Stockholders
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of
May 29, 2020 12:37 pm ET
Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa® P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer’s Disease
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust
May 13, 2020 09:45 am ET
 Quanterix’ Simoa Technology Sets New Standard in Protein Detection
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully applied its
May 11, 2020 08:26 am ET
Researchers Develop Breakthrough COVID-19 Antibody Test with 1,000-Fold Sensitivity Improvement Using Quanterix’ Simoa Technology
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, announced that researchers have developed a sensitive and specific serology test using the company’s ultra-sensitive Simoa platform for the detection and measurement of anti-SARS-CoV-2 IgG, IgM, and IgA antibodies against fo
May 05, 2020 04:05 pm ET
 Quanterix Corporation Releases Operating Results for First Quarter 2020
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ended March 31, 2020.
May 01, 2020 11:00 am ET
Quanterix CEO and Powering Precision Health Founder Kevin Hrusovsky to Appear on Passionate Pioneers Podcast
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chief Executive Officer, President and Chairman Kevin Hrusovsky, also the founder of the
Apr 28, 2020 02:45 pm ET
Quanterix to Release First Quarter 2020 Financial Results and Host Conference Call on May 5, 2020
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2020 after the close of trading on Tuesday, May 5, 2020. Company management will host a conference call at 4:30
Apr 24, 2020 06:04 pm ET
Quanterix Announces Simoa® Success Grant Program to Accelerate Promising Infectious Disease & Immunology Research
Quanterix Corporation (NASDAQ: QTRX), a company digitizing analysis to advance the science of precision health, today announced a call for proposals for the Simoa® Success Grant Program. Designed to support United States-based investigators addressing basic or pre-clinical questions in Infectious Disease and Immunology, the Simoa® Success Grant
Apr 10, 2020 04:00 pm ET
Quanterix’ Ultra-Sensitive Simoa Technology Demonstrates Promise for COVID-19 Acute Care, Immune Response Monitoring and Treatment
Quanterix Corporation (NASDAQ: QTRX), a company revolutionizing digital biomarkers, joined forces with PPH in the fight against COVID-19. The first session, in a series of Think Tank Webinars designed to stimulate and catalyze biomarker innovations, was held on April 2, 2020 with world leading virology and epidemiology experts. This follows clo
Apr 09, 2020 01:15 pm ET
Quanterix Corporation to Participate in the 19th Annual Needham Virtual Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chief Executive Officer, President and Chairman Kevin Hrusovsky will present at the
Mar 27, 2020 09:45 am ET
Quanterix Statement on COVID-19 Preparedness, Resiliency Efforts and Business Continuity
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the following statement amid the continued COVID-19 global crisis, severely impacting public health and the economy.
Mar 09, 2020 04:05 pm ET
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2019
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2019.
Feb 21, 2020 04:32 pm ET
Quanterix Corporation to Release Fourth Quarter 2019 Financial Results on March 9, 2020 and Present at Multiple Upcoming Healthcare Conferences
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourth quarter 2019 after the close of trading on Monday, March 9, 2020. Company management will host a conference call at 4:30 p.m., EST to discuss Quanterix’ f
Jan 31, 2020 10:04 am ET
Quanterix’ Simoa Technology Advances the Field Toward a Sports-Related Concussion Blood Test
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that researchers have successfully applied its ultra-sensitive Simoa technology to generate data on the value of blood biomarkers as research tools to study pathophysiological mechanisms
Jan 10, 2020 02:03 pm ET
Quanterix Corporation to Present at 38th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its President, Chairman and Chief Executive Officer, Kevin Hrusovsky, will be presenting on the company’s growth and vision for the fourth consecutive year at the
Nov 06, 2019 04:01 pm ET
Quanterix Corporation Releases Operating Results for Third Quarter 2019
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three and nine months ended September 30, 2019.
Nov 04, 2019 04:00 pm ET
Siemens Healthineers Enters into License and Supply Arrangement with Quanterix for Access to Neurofilament Light (Nf-L) Antibodies to Develop Nf-L Assays
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will al
Oct 25, 2019 09:13 am ET
Quanterix Simoa Technology Unlocks Low-Level Markers Critical to Rapid Triage Test in Study for Active Pulmonary Tuberculosis
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology was used, in a recent study, as a rapid test for the triage of adult patients with persistent cough suspected to have active pulmonary tuberculosis (TB). The study details the accuracy of the rapid
Oct 22, 2019 04:30 pm ET
Quanterix to Release Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.
Oct 03, 2019 09:00 am ET
Quanterix Announces Recipients of Annual Accelerator Grant Program
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Shelli Kesler, Ph.D., and Ashley Henneghan, Ph.D., MSN, from the School of Nursing at the University of Texas at Austin, as the winners of its annual Accelerator Grant Program for their research proposa
Sep 24, 2019 01:14 pm ET
Powering Precision Health Announces 2019 Summit
“Powering Precision Health has become a global movement to transform healthcare by measuring the continuum from health to disease at the molecular structure and individual level using digital biomarkers,” explained Kevin Hrusovsky, PPH Founder. “Our quest here is to rapidly advance technologies and science via collaboration to enable routine biomarker measurements at an individual level to personalize one’s health journey. The ultimate goal is for every individual to routinely know their individual biomarker healthy base line profile and then to see any deviation quickly to enable effective di
Sep 16, 2019 06:21 pm ET
Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology and Nf-L assays were used in many of the groundbreaking research and treatment developments presented at the
Sep 11, 2019 08:00 am ET
Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology has been referenced in more than 50 new research studies to be presented at the
Aug 13, 2019 04:21 pm ET
Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $69.0 million.
Aug 09, 2019 07:45 am ET
Quanterix Prices Public Offering of Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. Quanterix has also granted the underwriters a 30-day opti
Aug 07, 2019 04:23 pm ET
Quanterix Announces Proposed Public Offering of Common Stock
Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price. All of the shares in the offering will be sold by Quanterix. The offering is subject to market and other conditions, and there can be no assurance as to whet
Aug 06, 2019 08:30 am ET
Quanterix Corporation Releases Operating Results for Second Quarter 2019
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three and six months ended June 30, 2019.
Jul 31, 2019 09:00 am ET
Quanterix to Present at the Canaccord Genuity 39th Annual Growth Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the
Jul 30, 2019 10:30 am ET
Quanterix to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, August 6, 2019
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for second quarter 2019 before the start of trading on Tuesday, Aug. 6, 2019. Company management will host a conference call at 10 a.m., EDT to d
Jul 26, 2019 11:16 am ET
Sarah Hlavinka Elected to Quanterix Board of Directors
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has further strengthened its Board of Directors with the election of Sarah Hlavinka by the Company’s shareholders. Hlavinka succeeds Douglas G. Cole, M.D., who did not stand for re-election.
Jul 11, 2019 01:30 pm ET
Quanterix to Convene Leading Industry Researchers at Alzheimer’s Association International Conference 2019 Following Closing of UmanDiagnostics Acquisition
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, marks the end of the first half of 2019 with major milestones as it continues to expand its footprint in neurology and lead the digital biomarker revolution across healthcare. Most recently, on July 1, Quanterix announced it h
Jun 28, 2019 12:15 pm ET
Quanterix Announces Kevin Hrusovsky, Chairman and Chief Executive Officer, and Founder of Powering Precision Health, as EY Entrepreneur Of The Year® 2019 Award Winner in New England
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of
Jun 26, 2019 04:00 pm ET
Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recog
Jun 04, 2019 04:00 pm ET
Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common stock last week, raising $49.7 million in gross proceeds. Additionally, Quanterix will unveil its Simoa HD-X Analyzer™,
May 29, 2019 04:00 pm ET
Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to
May 16, 2019 10:30 am ET
Quanterix Announces $50,000 in Grants to Support Promising Oncology Research
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program wi
May 09, 2019 04:00 pm ET
Quanterix Corporation Releases Operating Results for First Quarter 2019
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ended March 31, 2019.
May 06, 2019 11:30 am ET
Quanterix’ Simoa Technology Powers More Than 85 Percent of Neurofilament Light Biomarker Research to be Unveiled at American Academy of Neurology Annual Meeting
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology is the driving force behind 36 of the 42 – nearly 86 percent – Nf-L abstracts being presented at the
May 02, 2019 04:00 pm ET
Quanterix to Release First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019. Company management will host a c
Apr 18, 2019 07:50 am ET
New Research Coverage Highlights Asanko Gold, Herc, Mitcham Industries, TRI Pointe Group, Quanterix, and Polar Power — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Asanko Gold Inc. (NYSE:AKG), Herc Holdings Inc. (NYSE:HRI), Mitcham...
Mar 28, 2019 04:00 pm ET
Quanterix Appoints Amol Chaubal as Chief Financial Officer
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Amol Chaubal to the position of Chief Financial Officer (CFO), effective April 12, 2019. Amol replaces Joseph Driscoll, who is stepping down from his curre
Mar 07, 2019 04:00 pm ET
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months and twelve months ended Dec. 31, 2018.
Feb 26, 2019 04:00 pm ET
Quanterix to Release Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Thursday, March 7, 2019
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019. Company management will host a conf
Feb 21, 2019 02:45 pm ET
Quanterix to Present at Multiple Upcoming Healthcare Conferences
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will be presenting and hosting one-on-one meetings with investors a
Jan 14, 2019 11:45 am ET
Quanterix to Present at 21st Annual Needham Growth Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will be presenting at the
Jan 10, 2019 12:00 pm ET
Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the much-anticipated full launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional mul
Jan 04, 2019 04:17 pm ET
Quanterix Marks One-Year Anniversary of IPO with Key Milestones Accelerating Healthcare Disruption Ahead of Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, is marking a little over one year since becoming a public company with significant milestones on its path toward revolutionizing healthcare. Quanterix’ Chief Executive
Nov 26, 2018 01:00 pm ET
Quanterix to Present at the Evercore ISI HealthCONx Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Evercore ISI HealthCONx Conference on Thursday,
Nov 21, 2018 08:15 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics — New Research Emphasizes Economic Gr
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Okta, Inc. (NASDAQ:OKTA), One Horizon Group, Inc. (NASDAQ:OHGI),...
Nov 13, 2018 04:00 pm ET
Quanterix to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the
Nov 07, 2018 09:00 am ET
Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced an Early Access Program for the latest advance in Simoa Sensitivity assays for oncology. The Early Access test bed will make available a new 10 plex ass
Nov 01, 2018 04:00 pm ET
Quanterix Corporation Releases Operating Results for Third Quarter 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months and nine months ended September 30, 2018.
Oct 25, 2018 04:05 pm ET
Quanterix to Release Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 1, 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for third quarter 2018 after the close of trading on Thursday, November 1, 2018. Company management will hos
Oct 22, 2018 04:30 pm ET
Quanterix Announces Collaboration with OncoGenesis to Develop Cervical Screening Test
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration agreement with OncoGenesis, a molecular protein-based cervical screening company, to develop a quantitative, protein biomarker diagnost
Oct 09, 2018 12:00 am ET
Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology has been highlighted in 35 new research studies to be presented at the
Sep 26, 2018 09:00 am ET
Quanterix’ Simoa Technology Reveals Link Between Soccer Headers and Concussions for the First Time
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced researchers have successfully applied its Simoa technology to reveal a correlation between heading a soccer ball and an increase in protein biomarkers known to be indicativ
Sep 18, 2018 10:45 am ET
Quanterix CEO Leads Webinar on How Digital Biomarkers are Empowering Drug Development
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky, will lead a webinar on Wednesday, Sept. 19 at 11 a.m., EDT on the power of biomarkers to disrupt
Sep 12, 2018 05:15 pm ET
Quanterix Announces Termination of License Agreement with bioMérieux
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the consolidation of its licensing position and reestablishment of control of its intellectual property in the in vitro diagnostics (IVD) field. The termination of t
Sep 05, 2018 09:00 am ET
Quanterix to Speak at Wells Fargo Securities 2018 Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the
Aug 08, 2018 04:00 pm ET
Quanterix Corporation Releases Operating Results for Second Quarter 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months and six months ended June 30, 2018.
Aug 06, 2018 09:32 am ET
Simoa Technology Unlocks Insights from Previously Obscure Biomarker
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced its ultra-sensitive Simoa technology is making it possible for researchers to uncover significant novel applications for the brain biomarker neurofilament light chain (NfL) to advance the
Jul 30, 2018 09:00 am ET
Quanterix to Present at the Canaccord Genuity 38th Annual Growth Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the
Jul 26, 2018 09:00 am ET
Quanterix to Release Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for second quarter 2018 after the close of trading on Wednesday, August 8, 2018. Company management will host
Jul 23, 2018 01:00 pm ET
Quanterix’ Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that researchers have uncovered novel links between several blood-based biomarkers and the diagnosis of brain injuries and chronic neuropsychological symptoms in military p
Jun 13, 2018 09:30 am ET
EY Announces Kevin Hrusovsky, President, Chairman and Chief Executive Officer of Quanterix and Founder of Powering Precision Health as an Entrepreneur Of The Year® 2018 Award Finalist in the New Engla
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, President, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been named by EY as a finalist for the Entrepreneur Of T
May 09, 2018 04:00 pm ET
Quanterix Corporation Releases Operating Results for First Quarter 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the first quarter 2018.
May 02, 2018 09:00 am ET
Quanterix to Release First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2018 after the close of trading on Wednesday, May 9, 2018. Com
Apr 27, 2018 09:00 am ET
Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has surpassed an important milestone that its technology has been highlighted in more than 100 third-party, peer-reviewed publications in neurology. Driven by increased
Mar 21, 2018 11:00 am ET
Quanterix to Present at Needham and Company’s 17th Annual Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at
Mar 20, 2018 09:00 am ET
Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with
Mar 14, 2018 04:05 pm ET
Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously a
Mar 08, 2018 08:00 am ET
New Research Demonstrates Enhanced Sensitivity for Acute HIV Detection Using Quanterix’ Simoa Technology
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its industry-leading single molecule array, or
Mar 07, 2018 12:56 pm ET
Quanterix to Present at the Cowen and Company 38th Annual Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the
Feb 08, 2018 10:00 am ET
Quanterix to Present at The LEERINK Partners 7th Annual Global Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will be presenting at the LEERINK Partners 7th Annual Global Healthcare Summit. The pr
Jan 04, 2018 09:03 am ET
Quanterix Corporation to Present at 36th Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference. The presentatio

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.